IGF::OT::IGF Phase I SBIR Topic 359 Title: Device Strategy for Selective Isolation of Oncosomes and Non-Malignant Exosomes09/15/2017 - 06/14/2018Firm Fixed Price

IGF::OT::IGF 第一阶段 SBIR 主题 359 标题：选择性分离肿瘤体和非恶性外泌体的设备策略09/15/2017 - 06/14/2018固定价格

• 批准号: 9570538
• 负责人: Annette Marleau
• 金额: $ 29.93万
• 依托单位: AETHLON MEDICAL, INC.
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-09-15 至 2018-06-14
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9570538
• 关键词: Affinity; Agglutinins; Chondroitin Sulfate Proteoglycan; Clinical; Complex; Devices; Epitopes; Fiber; Galanthus nivalis; Hemofiltration; Lectin; Magnetism; Mannose; Medical; Membrane Glycoproteins; Methods; Non-Malignant; Phase; Plasma; Population; Price; Recovery; Research; Research Personnel; Small Business Innovation Research Grant; Standardization; Techniques; Technology; Tissues; Tumor-Derived; Vesicle; Virus; Work; base; clinical care; exosome; melanoma; tumor

To provide a platform suitable for purification of tumor-derived vesicles and to separate them from other tissue-derived vesicles in biofluids, we propose a two-step approach: 1) Aethlon Medical’s Hemopurifier device for isolation of the total exosome population from biofluids such as plasma. This affinity biofiltration technology employs hollow-fiber hemofiltration cartridges (average 200 nm pores) containing the lectin Galanthus nivalis agglutinin (GNA) as an affinity agent, which has been leveraged for capture of a broad spectrum of viruses of similar sizes and high mannose-glycoprotein surfaces as exosomes. This clinically-used device has been scaled down to a bench-top version capable of filtering large volumes of complex biofluids, thereby overcoming limitations of current exosome isolation techniques. 2) Magnetic immunocapture of tumor exosomes using the mAb 225.28 recognizing an epitope of chondroitin sulfate proteoglycan 4 expressed on tumor exosomes. The Co-Investigators, Drs. Whiteside and Ferrone, have demonstrated the ability to perform magnetic isolation of melanoma exosomes using mAb 225.28. By leveraging a device platform specialized for rapid processing biofluids followed by immunocapture with mAb 225.28, the proposed work aims to standardize an exosome isolation method from complex biofluids that will be suitable for automated workflows in research and clinical care.

为了提供一个适合于肿瘤衍生蔬菜纯化的平台，并将其与生物流体中的其他组织衍生蔬菜分开，我们提出了一种两步方法：1）Aethlon Medical的象征性象征性象征，以分离出从血浆等生物群体中的总外生物种群。这种亲和力生物过滤技术采用空心纤维血液过滤术（平均200 nm毛孔），其中包含Galanthus nivalis凝集素（GNA）作为亲和力剂，该剂已被利用，该剂已被捕获以捕获相似大小的病毒和高甘露糖糖糖蛋白表面的广泛病毒。该临床中使用的设备已缩减为台式版本，能够过滤大量的复杂生物流体，从而克服了当前外泌体隔离技术的局限性。 2）使用MAB 225.28识别硫酸软骨素蛋白聚糖4的表位在肿瘤外泌体上表达的磁性外泌体的磁性免疫接触。共同投资者，博士。 Whiteside和Ferrone证明了使用MAB 225.28进行黑色素瘤外泌体进行磁分离的能力。通过利用专门用于快速加工生物流体的设备平台，然后使用MAB 225.28进行免疫接管，拟议的工作旨在通过复杂的生物流体进行标准化外泌体隔离方法，适合于研究和临床护理中的自动化工作流程。